Harnessing AI For Faster And More Efficient Development And Manufacturing Of Gene Therapies

By María Iglesias, Head of Digital & IT, Jens Keune, Data Science & Digital Product Manager

As the biopharmaceutical industry continues to evolve, the integration of Artificial Intelligence (AI) into gene therapy manufacturing is becoming not just advantageous, but essential. At Viralgen, we do not view AI as a stand-alone value driver; instead, we demonstrate how it directly supports our mission: advancing gene therapy manufacturing and technology to transform lives. Our commitment is to partner with clients across the entire development pathway — from early process design through to large-scale commercial manufacturing — delivering the highest-quality gene therapy products, at the right time and at the right scale, to meet patient needs worldwide.

Drawing on Viralgen’s extensive experience as a Contract Development and Manufacturing Organization (CDMO) with a proven track record in adeno-associated virus (AAV) production, we showcase practical applications of AI in gene therapy manufacturing. Through real-world case studies, we highlight how AI-driven tools enhance efficiency, quality, and scalability, while also addressing the challenges, infrastructure requirements, and organizational mindset needed for successful implementation.